Evaxion, a clinical-stage TechBio company using AI to develop vaccines, will announce its first quarter 2026 financial results and provide a business update on May 7, 2026, before Nasdaq opens. The company will host a conference call and webcast to present the results and answer questions. Evaxion's AI-Immunology™ platform focuses on creating novel vaccine candidates for cancer and infectious diseases, aiming to address significant medical needs. Investors and interested parties can register to join the live event or access the webcast recording afterward on the company's website.
Bill C-22 in Canada faces criticism from tech leaders and experts like Yanik Guillemette, who warn it threatens the digital economy by undermining data privacy and encryption. Major companies including Meta, Apple, and Signal express concerns that th...
Canada's proposed Bill C-22 faces strong opposition from global tech leaders and privacy advocates who warn it threatens the country's digital economy by undermining data privacy and encryption. Key companies like Meta, Apple, and Signal argue the la...
Golden Heaven Group Holdings Ltd. and several defendants have agreed to a $1.7 million settlement in a class action lawsuit related to the company's 2023 IPO and subsequent stock purchases. The settlement, approved by the New York Supreme Court, cove...
Taseko Mines Limited announced a proposal to change its name to Trekor Metals Limited at its upcoming Annual General Meeting on June 24, 2026. The name change aims to reflect the company's expanded asset base and growth in North America’s copper sect...
Kaltura has won the Best Event AI Technology award at Eventex 2026 for the fourth consecutive year, highlighting its leadership in AI-driven event solutions. This year, Kaltura's new Agentic Avatars, which provide real-time, personalized conversation...
